159 related articles for article (PubMed ID: 19358342)
1. Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma.
Kaminski M
Cancer Biol Ther; 2007 Jul; 6(7):996-7. PubMed ID: 19358342
[No Abstract] [Full Text] [Related]
2. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
Rutar FJ; Augustine SC; Kaminski MS; Wahl RL; Siegel JA; Colcher D
Clin Lymphoma; 2001 Dec; 2(3):164-72. PubMed ID: 11779293
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
[TBL] [Abstract][Full Text] [Related]
4. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD
Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Friedberg JW; Fisher RI
Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
[TBL] [Abstract][Full Text] [Related]
6. The radioisotope contributes significantly to the activity of radioimmunotherapy.
Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of Non-Hodgkin's lymphoma.
Britton KE
J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
[No Abstract] [Full Text] [Related]
8. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
Goldenberg DM; Sharkey RM
J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
[No Abstract] [Full Text] [Related]
9. New strategies in radioimmunotherapy for lymphoma.
Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR
Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386
[TBL] [Abstract][Full Text] [Related]
10. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma.
Vose JM
Oncologist; 2004; 9(2):160-72. PubMed ID: 15047920
[TBL] [Abstract][Full Text] [Related]
11. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Macklis RM
Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications.
Wahl RL
J Nucl Med; 1998 Aug; 39(8 Suppl):1S. PubMed ID: 9708563
[No Abstract] [Full Text] [Related]
14. Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas.
Capizzi RL
Trans Am Clin Climatol Assoc; 2004; 115():255-72. PubMed ID: 17060972
[TBL] [Abstract][Full Text] [Related]
15. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
[TBL] [Abstract][Full Text] [Related]
16. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
[TBL] [Abstract][Full Text] [Related]
17. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
18. Durable responses reported with radioimmunotherapy in low-grade non-Hodgkin's lymphoma.
Oncology (Williston Park); 2002 Mar; 16(3):304, 326. PubMed ID: 15046389
[No Abstract] [Full Text] [Related]
19. Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma.
Smith S; Sweetenham JW
Future Oncol; 2007 Jun; 3(3):255-62. PubMed ID: 17547519
[TBL] [Abstract][Full Text] [Related]
20. Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab.
Hohenstein MA; Augustine SC; Rutar F; Vose JM
Semin Oncol; 2003 Apr; 30(2 Suppl 4):39-49. PubMed ID: 12728406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
